ECOR1 CAPITAL LLC
Q2 2025 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001587114 · CRD 167121 · SEC-registered investment adviser
$1.7B Reported Value Total

ECOR1 CAPITAL, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $3,914,180,012, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
5 funds · $3.4B gross asset value
Hedge Fund: $3.4B · Venture Capital Fund: $65.4M
Source: Form ADV filed 2026-03-30
Reported value
$1.7B
Quarter over quarter
+1.7%
Holdings
36
Top-10 concentration
77.3%

Filing Structure

Reports holdings for

  • NODELMAN OLEG (not a 13F filer in our records) · File #028-16767 · Q4 2014 – Q4 2014

Key People

Form ADV owners & control persons
Sarah Christine Marriott
MEMBER, CCO, COO
Oleg Nmn Nodelman
MANAGER
Scott Eric Perlen
CFO

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2025 13F record

Q2 2025 13F filing summary

Q2 2025 Form 13F portfolio summary
Period of report June 30, 2025
Filed August 14, 2025
Form 13F-HR
Reported value $1.7B
Positions 36
Change in reported value +0.2%
New positions 6
Exited positions 14
Position turnover 40.0%
Top-10 concentration 77.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
34 $2.3B
Q2 2026 13F
Filed Aug 14, 2026
31 $2.1B
Q1 2026 13F
Filed May 15, 2026
29 $2.4B
Q4 2025 13F
Filed Feb 17, 2026
28 $2.2B
Q3 2025 13F
Filed Nov 14, 2025
30 $2.1B
Q2 2025 13F
Filed Aug 14, 2025
36 $1.7B
Q1 2025 13F
Filed May 15, 2025
44 $1.7B
Q4 2024 13F
Filed Feb 14, 2025
55 $2.6B
Q3 2024 13F
Filed Nov 14, 2024
63 $2.9B
Q2 2024 13F
Filed Aug 14, 2024
55 $3.3B
Q1 2024 13F
Filed May 15, 2024
57 $4.0B
Q4 2023 13F
Filed Feb 14, 2024
51 $3.9B
Q3 2023 13F
Filed Nov 14, 2023
49 $3.0B
Q2 2023 13F
Filed Aug 14, 2023
51 $4.1B
Q1 2023 13F
Filed May 15, 2023
58 $3.1B
Q4 2022 13F
Filed Feb 14, 2023
66 $3.3B
Q3 2022 13F
Filed Nov 14, 2022
75 $3.4B
Q2 2022 13F
Filed Aug 15, 2022
78 $2.9B
Q1 2022 13F
Filed May 16, 2022
86 $3.2B
Q4 2021 13F
Filed Feb 14, 2022
75 $3.1B

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2025

Largest Q2 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 ZYME ZYMEWORKS INC $288.3M 17.06%
2 APLS APELLIS PHARMACEUTICALS INC $205.9M 12.19%
3 JAZZ JAZZ PHARMACEUTICALS PLC $181.1M 10.72%
4 ANAB ANAPTYSBIO INC $174.9M 10.36%
5 CRNX CRINETICS PHARMACEUTICALS IN $123.3M 7.3%
6 ITOS ITEOS THERAPEUTICS INC $106.6M 6.31%
7 CRSP CRISPR THERAPEUTICS AG $67.6M 4.0%
8 QURE UNIQURE NV $55.6M 3.29%
9 TNGX TANGO THERAPEUTICS INC $54.4M 3.22%
10 XNCR XENCOR INC $48.3M 2.86%
11 IMNM IMMUNOME INC $37.9M 2.25%
12 JANX JANUX THERAPEUTICS INC $34.0M 2.01%
13 LKFT GALAPAGOS NV $29.0M 1.72%
14 ETON ETON PHARMACEUTICALS INC $28.9M 1.71%
15 KURA KURA ONCOLOGY INC $24.2M 1.43%
16 AKRO AKERO THERAPEUTICS INC $23.5M 1.39%
17 MDGL MADRIGAL PHARMACEUTICALS INC $22.7M 1.34%
18 NGNE NEUROGENE INC $19.0M 1.13%
19 VRNA VERONA PHARMA PLC $18.9M 1.12%
20 TECX TECTONIC THERAPEUTIC INC $18.6M 1.1%

Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings